- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03163173
A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects
GC4419 is being studied to treat and prevent oral mucositis (painful inflammation) in cancer patients who receive radiation and chemotherapy.
In this study, GC4419 will be mixed with a small amount of radioactive material in order to find out how much study drug is in the blood and to see how the drug is processed and eliminated from the body. The safety and how subjects tolerate the study drug will also be studied.
Study Overview
Detailed Description
This is an open-label, single-dose, 1-period study.
On Day 1, a single 30 mg (~100 μCi) dose of [14C]GC4419 will be administered as an IV infusion over 15 minutes. Blood, urine, and fecal samples will be collected to measure total radioactivity (plasma, whole blood, urine, and fecal samples), for GC4419 and its metabolites GC4520 and GC4570 concentrations (plasma, urine, and fecal samples), and for metabolic profiling (plasma, urine, and fecal samples), as total amounts of radioactivity allow, for at least 168 hours postdose (Day 8).
If discharge criteria are not met on Day 8, collection of blood will be collected approximately every 72 hours, and urine and feces collection will continue in 24-hour intervals thereafter (for determination of total radioactivity and metabolic profiling only) until the discharge criteria are met or up to a maximum stay of 28 days (Day 29).
The clinic will attempt to contact all subjects (including subjects who terminate the study early) using their standard procedures approximately 14 days after the last sample collection to determine if any adverse event has occurred since the last sample collection.
Six (6), healthy, adult, non tobacco using, male subjects will be enrolled.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, adult, male, 19-55 years of age, inclusive, at screening.
- Continuous non-smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study.
- Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
- No clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs
- A non-vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond dosing.
- Must agree not to donate sperm from dosing until 90 days after dosing.
- Be willing and able to comply with the protocol.
Exclusion Criteria:
- Subject is mentally or legally incapacitated
- History or presence of clinically significant medical or psychiatric condition or disease
- History or presence of alcoholism or drug abuse within the past 2 years prior to dosing.
- History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
- Regularly has less than 1 bowel movement every 2 days.
- Recent history (within 2 weeks of Day 1) of abnormal bowel habits
- Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
- Blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg
- Heart rate is lower than 40 bpm or higher than 99 bpm
- Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing and throughout the study.
- Has been on a diet incompatible with the on study diet
- Donation of blood or significant blood loss within 56 days prior to dosing.
- Plasma donation within 7 days prior to dosing.
- Has received radiolabeled substances or has been exposed to radiation sources over the past 12 months or is likely to receive radiation exposure or radioisotopes within the next 12 months such that participation in this study would increase their total exposure beyond the recommended levels considered safe
- Participation in another clinical study within 28 days prior to dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm - Treatment Group
30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
|
30 mg (~100 μCi) dose of [14C]GC4419
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mass balance of GC4419
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Total radioactivity found in biological specimens
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Total radioactivity in plasma (AUC0-t)
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
The area under the concentration time or concentration equivalent time curve, from time 0 to the last observed non-zero concentration (Ct)
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Major metabolites in biological specimens.
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Total concentrations of GC4419 and its metabolites found in biological specimens
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
14C radioactivity in whole blood
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Change over time in percentage of 14C radioactivity in whole blood
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Total radioactivity in plasma (Cmax)
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Maximum observed concentration or concentration equivalent
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Total radioactivity in plasma (Tmax)
Time Frame: From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Time to reach Cmax
|
From dosing until discharge criteria are met [up to a maximum stay of 28 days postdose (Day 29)]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jon T Holmlund, MD, Galera Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GTI-4419-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on GC4419
-
Galera Therapeutics, Inc.CompletedRenal ImpairmentUnited States
-
Galera Therapeutics, Inc.CompletedRadiation Induced Oral MucositisUnited States, Canada, Puerto Rico
-
Galera Therapeutics, Inc.TerminatedCovid19 | SARS-CoV-2 InfectionUnited States
-
Galera Therapeutics, Inc.Terminated
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.CompletedHead and Neck Cancer | Oral MucositisSpain, Switzerland, Belgium, Poland, Germany, Czechia
-
Galera Therapeutics, Inc.CompletedSquamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the OropharynxUnited States
-
Galera Therapeutics, Inc.CompletedOral MucositisUnited States, Puerto Rico, Canada
-
Galera Therapeutics, Inc.M.D. Anderson Cancer CenterCompletedPancreatic Cancer | Stereotactic Body Radiation TherapyUnited States
-
Galera Therapeutics, Inc.Completed